Demetrius Matassov, Ph.D.
Affiliations: | 2005 | City University of New York, New York, NY, United States |
Area:
Cell Biology, Microbiology BiologyGoogle:
"Demetrius Matassov"Parents
Sign in to add mentorZahra Zakeri | grad student | 2005 | CUNY | |
(Characterization and mechanism of influenza A virus induced cell death.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Woolsey C, Borisevich V, Agans KN, et al. (2023) A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus. The Journal of Infectious Diseases |
Woolsey C, Cross RW, Agans KN, et al. (2022) A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. Plos Neglected Tropical Diseases. 16: e0010433 |
Woolsey C, Jankeel A, Matassov D, et al. (2020) Immune correlates of postexposure vaccine protection against Marburg virus. Scientific Reports. 10: 3071 |
Clarke DK, Xu R, Matassov D, et al. (2020) Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. The Lancet. Infectious Diseases |
Cross RW, Xu R, Matassov D, et al. (2019) Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. The Journal of Clinical Investigation |
Woolsey C, Geisbert JB, Matassov D, et al. (2018) Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. The Journal of Infectious Diseases |
Matassov D, Mire CE, Latham T, et al. (2017) Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. Journal of Virology |
Nasar F, Matassov D, Seymour RL, et al. (2017) Recombinant Isfahan virus and vesicular stomatitis virus vaccine vectors provide durable, multivalent, single dose protection against lethal alphavirus challenge. Journal of Virology |
Matassov D, Marzi A, Latham T, et al. (2015) Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. The Journal of Infectious Diseases. 212: S443-51 |
Mire CE, Matassov D, Geisbert JB, et al. (2015) Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 520: 688-91 |